Headlines about Trevena (NASDAQ:TRVN) have been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trevena earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.5414988580789 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media stories that may have impacted Accern’s analysis:
- Barclays Lowers Trevena (TRVN) to Equal Weight (americanbankingnews.com)
- “There are real geotechnical problems there” says Minister about South Taylor Hill (energeticcity.ca)
- Zacks Investment Research Upgrades Trevena (TRVN) to “Buy” (americanbankingnews.com)
- BC tightening up highway maintenance contracts (e-know.ca)
- Province has no plan to replace Greyhound in Northern BC (cbc.ca)
Several brokerages recently commented on TRVN. HC Wainwright raised their target price on Trevena to $7.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. Zacks Investment Research cut Trevena from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a report on Saturday, January 20th. Finally, Oppenheimer reissued a “buy” rating on shares of Trevena in a report on Thursday, March 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $7.06.
Trevena (NASDAQ:TRVN) last released its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.02. analysts predict that Trevena will post -0.89 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3343470/trevena-trvn-given-media-impact-rating-of-0-18.html.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.